Table 1.
Baseline characteristics of study population (N = 127)
| Characteristic | IC without VEN (N = 44) | LIT without VEN (N = 29) | LIT with VEN (N = 54) | P value |
|---|---|---|---|---|
| Age (y) | 63 (60-76) | 67 (61-75) | 68 (60-77) | < .0001 |
| ECOG performance status at diagnosis | ||||
| 0 | 15 (34) | 3 (10) | 9 (17) | .06 |
| 1 | 27 (61) | 21 (72) | 39 (72) | |
| 2 | 2 (5) | 5 (17) | 6 (11) | |
| AML type | ||||
| De novo AML | 35 (80) | 20 (69) | 30 (56) | .04 |
| Secondary AML | 9 (20) | 9 (31) | 24 (44) | |
| ELN 2017 risk | ||||
| Favorable∗ | 9 (20) | 4 (14) | 10 (19) | .66 |
| Intermediate | 16 (36) | 11 (38) | 14 (26) | |
| Adverse | 19 (43) | 14 (48) | 30 (56) | |
| Mutations | ||||
| NPM1 | 12 (27) | 7 (24) | 12 (22) | .85 |
| FLT3-ITD | 9 (20) | 7 (24) | 6 (11) | .26 |
| IDH1/IDH2 | 11 (25) | 3 (10) | 14 (26) | .22 |
| KRAS/NRAS | 5 (11) | 3 (10) | 12 (22) | .23 |
| RUNX1 | 3 (7) | 1 (3) | 12 (22) | .02 |
| ASXL1 | 4 (9) | 0 | 9 (17) | .06 |
| TP53 | 8 (18) | 6 (21) | 7 (13) | .62 |
Continuous variables are listed as median (range) and categorical variables as N (%) or n/N (%).
ECOG, Eastern Cooperative Oncology Group; ELN, European LeukemiaNet; VEN, venetoclax.
∗
Two patients (5%) in the IC group had core-binding factor AML.